Skip to main content
Premium Trial:

Request an Annual Quote

Danaher Completes Beckman Coulter Acquisition

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Danaher has completed its acquisition of Beckman Coulter following the expiration last night of a subsequent offering period in the tender offer.

As reported by GenomeWeb Daily News earlier this week, Danaher had completed the tender offer last Friday, with about 88.08 percent of all outstanding shares having been tendered. Following the subsequent offering period, a total of 66,168,634 shares of Beckman common stock representing around 92.38 percent of the outstanding shares had been validly tendered and not withdrawn.

Beckman stockholders who did not tender their shares will receive the offer price of $83.50 per share.

The firms inked the $6.8 billion deal in February. Beckman will become part of Danaher's Life Sciences and Diagnostics segment, joining the AB Sciex, Leica, Radiometer, and Molecular Devices businesses. It provides Danaher with one of the world's largest diagnostics players. Beckman reported full-year 2010 clinical diagnostics sales of $3.21 billion, up 15 percent year over year.